---
title: "Cardio Diagnostics Holdings, Inc. 2026: Revenue $5.36K, EPS ($0.51) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295276302.md"
description: "Cardio Diagnostics Holdings reported Q2 2026 results with $5.36K revenue and a net loss of $1.5M, or diluted EPS of ($0.51). Revenue declined 28.3% YoY, though the net loss narrowed by 10.8%. The company is in an early commercialization stage, shifting strategy toward non-reimbursement channels like telemedicine while securing CPT codes and initial commercial coverage. Operational updates include launching an in-house lab and initiating reagent shipments for India."
datetime: "2026-08-07T20:35:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295276302.md)
  - [en](https://longbridge.com/en/news/295276302.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295276302.md)
generator: "portal-rs"
---

# Cardio Diagnostics Holdings, Inc. 2026: Revenue $5.36K, EPS ($0.51) — 10-Q Summary

Cardio Diagnostics Holdings, Inc. reported results for the 2026 quarter, with nominal revenue of $5.36K and a net loss of ($1.5M), or diluted loss per share of ($0.51), reflecting ongoing commercialization and operating investment.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$5.36K

$7.48K

(28.3%)

Net income²

($1.5M)

($1.68M)

10.8%

Diluted EPS³

($0.51)

($0.97)

47.4%

*¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per common share”.*

**Business Highlights**

-   Revenue remained nominal at $5.4K for the quarter ($8.0K year-to-date), reflecting the company's early commercialization stage.
-   Go-to-market strategy shifted toward non-reimbursement channels including telemedicine, concierge/functional practices, employers, unions and benefit brokers.
-   Reimbursement progress included secured CPT PLA codes, CMS gapfill rates at $854 per test and initiation of out-of-network commercial claims; the company secured its first commercial coverage with AHP.
-   Operationally, the company brought up an in-house high-complexity CLIA lab and began testing (New York pending license) and started reagent shipments for an India rollout.
-   Ongoing activities include clinical and economic studies, pursuing Medicare and broader commercial coverage, expanding product pipeline (stroke, heart failure, diabetes) and seeking partnerships.

Original SEC Filing: Cardio Diagnostics Holdings, Inc. \[ CDIO \] - 10-Q - Aug. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CDIOW.US](https://longbridge.com/en/quote/CDIOW.US.md)
- [CDIO.US](https://longbridge.com/en/quote/CDIO.US.md)

## Related News & Research

- [Cardio Diagnostics wins federal CLIA license for high-complexity Iowa City lab](https://longbridge.com/en/news/296229399.md)
- [Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City | CDIO Stock News](https://longbridge.com/en/news/296230090.md)
- [1 Cheap Stock Under $10 for Aggressive Investors to Buy on the Dip](https://longbridge.com/en/news/297683938.md)
- [Lowe’s announces dividend of R$ 0.22 per unit, payable Nov. 10](https://longbridge.com/en/news/297828119.md)
- [UTime answers shareholder questions ahead of Sept. 10 extraordinary meeting](https://longbridge.com/en/news/297695422.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**